Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
Allergy · 2026-11 · 81 (11) · 3985-4004
DOI: 10.1111/all.70504 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 04.09.2026. Verfasst von Musa R Khaitov und 43 weiteren Autor:innen. Beteiligte Einrichtung: National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Seasonal, Pollen, Desensitization, Immunologic, Betula. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Generium.
Abstract (Originalsprache)
Background
We have recently reported the preclinical characterization of a recombinant birch pollen allergy vaccine based on a fusion protein, AB ‐ PreS , consisting of allergen‐derived peptides fused to the hepatitis B virus ( HBV )‐derived PreS surface protein as immunological carrier.
Objective
To investigate in a clinical study the usefulness of the AB ‐ PreS vaccine, termed GNR ‐127, for allergen‐specific immunotherapy of birch pollen allergy.
Methods
Stage 1 of the study, an open‐label Phase I study, determined among three doses (20 μg: n = 6; 40 μg: n = 6; 80 μg: n = 6) administered as Aluminum‐hydroxide‐adsorbed vaccines subcutaneously five times in monthly intervals, the highest tolerated doses. In the following Stage 2, randomized patients (placebo: n = 45; 40 μg: n = 43; 80 μg: n = 44) received in a single‐blind, placebo‐controlled Phase II study monthly up to five pre‐seasonal injections. Safety monitoring followed the Medical Dictionary for Regulatory Activities (MedDRA); efficacy parameters were determined according to the European Academy for Allergy and Clinical Immunology ( EAACI ) guidelines; allergen‐specific antibodies and basophil sensitivity were determined by ELISA and basophil activation testing, respectively.
Results
A dose‐dependent reduction of the combined symptom medication score ( CSMS ) (40 μg: 17.41%; 80 μg: 24.13%) over placebo was observed which was significant for the 80 μg group and accompanied by the strongest induction of Bet v 1‐specific IgG (median 20‐fold increase) and a blunting of the seasonally boosted IgE response and basophil sensitivity. The vaccine showed an acceptable safety profile despite high administered doses.
Conclusion
A pre‐seasonal course of 5 monthly injections of GNR ‐127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1‐specific IgG response, paving the road for a Phase III efficacy study. Trial Registration ClinicalTrials.gov (Identifier: NCT07155499)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.
- Pirogov Russian National Research Medical University, Moscow, Russian Federation.
- Peoples' Friendship University of Russia (RUDN University) of Ministry of Science and Higher Education of the Russian Federation, Moscow, Russian Federation.
- Life Improvement by Future Technologies (LIFT) Center, Moscow, Russian Federation.
- Institute of Pharmacy n. a. A.P. Neliubin, I.M. Sechenov 1st MSMU of the MOH of Russia (Sechenov University), Moscow, Russian Federation.
- JSC "GENERIUM", Volginsky, Russian Federation.
ORCID-Profile: Musa R Khaitov, Maria G Byazrova, Evgenii V Smolnikov, Vladislav N Turenko, Valeriy V Smirnov, Olga G Elisyutina, George B Pasikhov, Veronika A Parshina, Darya K Bolyakina, Daria O Timoshenko, Elena A Latysheva, Oksana M Kurbacheva, Elena S Fedenko, Oksana A Markova, Dmitry A Kudlay, Alexander V Filatov, Daria S Kruchko, Rudolf Valenta
Förderung
- Generium
Zitieren
APA
Khaitov, M. R., Byazrova, M. G., Smolnikov, E. V., Turenko, V. N., Smirnov, V. V., Shilovskii, I. P., Shershakova, N. N., Medunitsyna, E. N., Elisyutina, O. G., Pashenkov, M. V., Pasikhov, G. B., Murugin, V. V., Parshina, V. A., Bolyakina, D. K., Primak, A. S., Lapyko, M. A., Danilycheva, I. V., Schubelko, R. V., Tsyvkina, A. A., …, & Skvortsova, V. I. (2026). Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy. Allergy, 81(11), 3985-4004. https://doi.org/10.1111/all.70504
Vancouver
Khaitov MR, Byazrova MG, Smolnikov EV, Turenko VN, Smirnov VV, Shilovskii IP, et al. Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy. Allergy. 2026;81(11):3985-4004. doi:10.1111/all.70504
BibTeX
@article{Khaitov2026,
author = {Khaitov, Musa R and Byazrova, Maria G and Smolnikov, Evgenii V and Turenko, Vladislav N and Smirnov, Valeriy V and Shilovskii, Igor P and Shershakova, Nadezhda N and Medunitsyna, Ekaterina N and Elisyutina, Olga G and Pashenkov, Mikhail V and Pasikhov, George B and Murugin, Vladimir V and Parshina, Veronika A and Bolyakina, Darya K and Primak, Anastasia S and Lapyko, Mariya A and Danilycheva, Inna V and Schubelko, Rosalia V and Tsyvkina, Anastasia A and Shartanova, Nataliia V and Timoshenko, Daria O and Isakova, Irina I and Latysheva, Tatiana V and Shulzhenko, Andrey E and Latysheva, Elena A and Kurbacheva, Oksana M and Fedenko, Elena S and Markova, Oksana A and Korotkevich, Ilya A and Yan, Violetta V and Gavrilova, Natalia A and Tikhomirova, Mariia V and Shevchenko, Ivan V and Agafonova, Alena A and Poroshin, Gregory N and Kudlay, Dmitry A and Filatov, Alexander V and Nazarova, Evgeniya V and Kruchko, Daria S and Goryachev, Dmitriy V and Merkulov, Vadim A and Ilina, Nataliya I and Valenta, Rudolf and Skvortsova, Veronica I},
title = {Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy},
journal = {Allergy},
year = {2026},
volume = {81},
number = {11},
pages = {3985--4004},
doi = {10.1111/all.70504}
}
EUVIMED